KPT-6566 is primarily investigated for its potential in cancer therapy, particularly in targeting and inhibiting specific proteins involved in tumor growth and survival. It is studied for its ability to induce cancer cell death by disrupting essential cellular pathways, making it a promising candidate for treating various malignancies. Researchers are exploring its efficacy in preclinical models to assess its potential as a targeted therapeutic agent, especially in cancers resistant to conventional treatments. Additionally, its role in modulating cellular processes like autophagy and apoptosis is of significant interest in developing novel anti-cancer strategies.